Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

NCT02594254 | Completed Phase 2

• 1 other identifier: C3J15-203-00
• Study Type: interventional
• Target: 135
• Locations: 1 country
• Sites: 10

Brief Summary

The purpose of this study is to evaluate if C16G2 Gel administered over a certain period of time either with a toothbrush or a custom dental tray can effectively kill bacteria in the mouth that cause dental cavities.

Conditions

Dental Caries

Outcome Measures

Primary Outcomes (3)

• Antimicrobial Activity of C16G2

  To assess the targeted antimicrobial activity of C16G2 Gel applications as measured by a reduction in Streptococcus mutans in saliva and dental plaque

  Evaluated over up to 5 months

• Total Oral Bacterial Levels

  Total bacterial levels will be evaluated by measuring cfu/ml counts of salivary and plaque bacteria

  Evaluated 7 days post last study drug administration

• Safety of C16G2 Gel Administrations assessed by performing targeted physical examinations, oral cavity exams, taking vital signs and collection of adverse events

  Safety will be assessed by performing targeted physical examinations, oral cavity exams, taking vital signs and collection of adverse events

  Up to 7 days post last study drug administration

Study Arms (7)

Study Arm 1

EXPERIMENTAL

Subjects in Study Arm 1 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush.

Drug: C16G2 Gel; Other: Placebo

Study Arm 2

EXPERIMENTAL

Subjects in Study Arm 2 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush and custom dental trays.

Drug: C16G2 Gel; Other: Placebo

Study Arm 3

EXPERIMENTAL

Subjects in open-label Study Arm 3 will receive 4 ml of 1600 µM study drug administrations for a total of 7 consecutive days. Subjects will receive 4 C16G2 Gel administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the clinic for 6 consecutive days. Study drug will be administered via a manual brush and custom dental trays.

Drug: C16G2 Gel

Study Arm 4

EXPERIMENTAL

Subjects in open-label Study Arm 4 will receive 4 ml 800 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.

Drug: C16G2 Gel

Study Arm 5

EXPERIMENTAL

Subjects in open-label Study Arm 4 will receive 4 ml of 1600 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.

Drug: C16G2 Gel

Study Arm 6

EXPERIMENTAL

If initiated, subjects in Study Arm 6 will receive 4 ml of 1600 µM study drug over a 7 day study drug administration period. Subjects will receive 4 C16G2 Gel or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.

Drug: C16G2 Gel; Other: Placebo

Study Arm 7

EXPERIMENTAL

If initiated, subjects in Study Arm 7 will receive 4 ml of 800 µM or 1600 µM study drug on a single day once a week or once a month for a total of 4 days of C16G2 Gel or placebo administration. Subjects will receive 4 study drug administrations on the day of dosing. Study drug will be administered via manual toothbrush and custom dental trays.

Drug: C16G2 Gel; Other: Placebo

Interventions

C16G2 Gel DRUG

Antimicrobial peptide

Also known as: Antimicrobial peptide

Study Arm 1; Study Arm 2; Study Arm 3; Study Arm 4; Study Arm 5; Study Arm 6; Study Arm 7

Placebo OTHER

Placebo

Study Arm 1; Study Arm 2; Study Arm 6; Study Arm 7

Eligibility Criteria

• Age: 12 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females, 12-75 years of age, inclusive, at the time the Assent and/or Informed Consent Form is signed
• Female subjects of childbearing potential, defined as not surgically sterile or at least two (2) years postmenopausal, must agree to use one of the following forms of contraception from screening through the last study visit: hormonal (oral, implant, or injection) begun \>30 days prior to screening; barrier (condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD). Acceptable contraceptive options may also include abstinence, relationship with same sex partner or partner who has had a vasectomy at least six (6) months prior to the screening visit
• Male subjects only: willing to use contraception or abstain from sexual activity beginning with the first exposure to study drug and continuing until discharged from the study due to completion or Early Termination
• Healthy, as determined by the Investigator (in consultation with the Medical Monitor, as needed), based on medical and dental history, concurrent illnesses, laboratory results, concomitant medications, oral cavity assessment, and targeted physical examination (extraoral, head and neck) during Screening Note: Subjects on a stable dose of medication may be eligible for screening and will be assessed by the Medical Monitor on a case-by-case basis.
• Have a minimum of 12 bicuspids and molars with a minimum of 8 molars and bicuspids NOT having restorations, crowns, sealants
• Demonstrated ability to expectorate ≥2 mL of stimulated saliva in 5 minutes
• Have a salivary S. mutans of 1.0 x 10\^5 colony forming units (CFUs)/mL or greater at Screening using mitis salivarius-bacitracin (MSB) agar plating
• Willing to refrain from using non-study dentifrice and other non-study oral care products (oral care rinses, fluoride products, etc.) during the study
• Willing to postpone elective dental procedures (e.g., dental cleanings) between Screening and final post-treatment visit (End of Study or Early Termination)
• Willing and able to comply with oral hygiene and diet instructions
• Has dentition adequate for custom dental tray gel application
• Able to understand and sign the Assent and/or Informed Consent Form prior to initiation of study procedures
• Able to communicate with the Investigator/study center personnel, understand and comply with the study requirements, and willing to return for protocol-specified visits at the appointed times

You may not qualify if:

• Advanced periodontal disease
• Active caries lesion(s) within 30 days prior to study drug administration (confirmed by comprehensive caries examination including standard radiographs if deemed necessary by the Investigator) Note: Subjects presenting with insipient, non-cavitated lesion(s) are not excluded
• Medical condition (e.g., artificial heart valve, history of infective endocarditis, cardiac transplant with valvular dysfunction, congenital heart disease or total joint replacement) for which antibiotics are recommended prior to dental visits and/or procedures
• Pathologic lesions of the oral cavity (suspicious or confirmed)
• Full dentures or orthodontic appliances, e.g., braces; Note: partial dentures, removable retainers and night guards are not excluded, provided that they are cleaned regularly throughout the duration of the study.
• Use of systemic antibiotics, topical oral antibiotics, or use of other drugs, which in the opinion of the Investigator could influence the study outcome, within 30 days prior to Screening and throughout the entire study.
• Medical history indicating the woman is pregnant, breastfeeding/lactating or has a positive urine pregnancy test
• Participation in a clinical trial or receipt of a non-FDA approved therapy within 30 days prior to study drug administration (depending on the specifics, participation in an observational study is not necessarily excluded)
• Prior participation in a C16G2 clinical trial and known to have received C16G2 active gel or mouth rinse Note: Placebo subjects are not excluded
• Presence of any condition or concurrent illness, which in the opinion of the Investigator, would compromise normal immune function (e.g., diabetes, rheumatoid arthritis, lupus, liver disease, organ transplant, etc.), interfere with the use of study dentifrice and oral care products, or interfere with the ability to comply with study requirements, or jeopardize the safety of the subject or the validity of the study results

Sponsors & Collaborators

• Armata Pharmaceuticals, Inc.: lead
• Vantage Data Designs, Inc.: collaborator
• SynteractHCR: collaborator
• Agility Clinical, Inc.: collaborator

Study Sites (10)

Imperial Beach Family Dentistry

Imperial Beach, California, 91932, United States

Location

Indiana University School of Dentistry

Indianapolis, Indiana, 46202, United States

Location

Tufts University

Boston, Massachusetts, 02111, United States

Location

John F. Pittaway, DMD

Kalispell, Montana, 59901, United States

Location

Plaza West II Dental Group

Kalispell, Montana, 59901, United States

Location

New York University College of Dentistry

New York, New York, 10010, United States

Location

East Carolina University

Greenville, North Carolina, 27834, United States

Location

University of Pennsylvania School of Dental Medicine

Philadelphia, Pennsylvania, 19104, United States

Location

Texas Baylor College of Dentistry

Dallas, Texas, 75246, United States

Location

Anthony Henegar, DDS, PA

Irving, Texas, 75063, United States

Location

MeSH Terms

Conditions

Dental Caries

Interventions

Antimicrobial Peptides

Condition Hierarchy (Ancestors)

Tooth Demineralization; Tooth Diseases; Stomatognathic Diseases

Intervention Hierarchy (Ancestors)

Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• Mark Wolff, DDS, PhD

  NYU Langone Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 28, 2015
• First Posted: November 3, 2015
• Study Start: November 1, 2015
• Primary Completion: June 1, 2016
• Study Completion: September 1, 2016
• Last Updated: August 1, 2019

Record last verified: 2019-07

Locations

US (10)